Aarti Pharmalabs Ltd
NSE:AARTIPHARM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aarti Pharmalabs Ltd
NSE:AARTIPHARM
|
IN |
Aarti Pharmalabs Ltd
Aarti Pharmalabs Ltd. engages in the manufacture and sale of pharmaceutical and nutraceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,400 full-time employees. The company went IPO on 2023-01-30. The firm delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. The company has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.
Aarti Pharmalabs Ltd. engages in the manufacture and sale of pharmaceutical and nutraceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,400 full-time employees. The company went IPO on 2023-01-30. The firm delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. The company has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.
Revenue Decline: Q3 revenue was INR 425 crores, down from INR 471 crores last year, due to delays and softness in key segments.
Profit Drop: Profit after tax fell to INR 44 crores from INR 74 crores a year ago, impacted by lower sales and operational costs.
CDMO Growth Solid but Timing Shift: CDMO revenue growth guidance for FY '26 stands, though exceeding targets now appears unlikely due to project delivery delays.
Plant Expansion Delays: Atali plant ramp-up faced initial challenges, pushing some revenue into next quarter; Xanthine capacity expansion on track for Q1 FY '27.
API Margin Pressure: The API segment continues to face margin and pricing pressure, though some recovery signs are emerging.
Muted Full-Year Growth: EBITDA for FY '26 now expected to be flat or up only marginally versus last year, due to plant delays and API headwinds.
Dividend Declared: Interim dividend of INR 1.5 per share announced for the quarter.
